Vaccine. Use of MDCK cells for production of live attenuated influenza vaccine.

[Giuseppe]

Vaccine. 2009 Jun 24. [Epub ahead of print]

Use of MDCK cells for production of live attenuated influenza vaccine.

Liu J, Shi X, Schwartz R, Kemble G. MedImmune, LLC., 3055 Patrick Henry Drive, Santa Clara, CA 95054, United States.


To develop a cell-based live attenuated influenza vaccine (LAIV) manufacturing process, several different cell lines were evaluated by comparing the titer of viruses after infection with LAIV strains. While several cell lines have been reported to support influenza virus replication, the degree of replication and the ability to support replication of LAIV strains have not been systematically examined. MDCK cells, which have been considered as potential substrates for influenza vaccine production were evaluated in addition to Vero, MRC-5, WI-38 and FRhL cells. MRC-5, WI-38 and FRhL cells produced low to moderate titers of virus with titers equal or below 5.0log(10) TCID(50)/mL. Both Vero and MDCK cells could support a higher level of virus replication for certain strains, however, Vero cells only produced high titers when grown in the presence of serum. MDCK cells supported high levels of vaccine virus production for multiple different LAIV subtypes in both serum containing and serum-free media. These results suggest that MDCK cell-based production can be used as an alternative production platform to the currently used egg-based LAIV production system.

PMID: 19559113 [PubMed - as supplied by publisher]
-
------

 

[the doctor]

Re: Vaccine. Use of MDCK cells for production of live attenuated influenza vaccine.

Vaccine. 2009 Jun 24. [Epub ahead of print]

Use of MDCK cells for production of live attenuated influenza vaccine.

Liu J, Shi X, Schwartz R, Kemble G. MedImmune, LLC., 3055 Patrick Henry Drive, Santa Clara, CA 95054, United States.


To develop a cell-based live attenuated influenza vaccine (LAIV) manufacturing process, several different cell lines were evaluated by comparing the titer of viruses after infection with LAIV strains. While several cell lines have been reported to support influenza virus replication, the degree of replication and the ability to support replication of LAIV strains have not been systematically examined. MDCK cells, which have been considered as potential substrates for influenza vaccine production were evaluated in addition to Vero, MRC-5, WI-38 and FRhL cells. MRC-5, WI-38 and FRhL cells produced low to moderate titers of virus with titers equal or below 5.0log(10) TCID(50)/mL. Both Vero and MDCK cells could support a higher level of virus replication for certain strains, however, Vero cells only produced high titers when grown in the presence of serum. MDCK cells supported high levels of vaccine virus production for multiple different LAIV subtypes in both serum containing and serum-free media. These results suggest that MDCK cell-based production can be used as an alternative production platform to the currently used egg-based LAIV production system.

PMID: 19559113 [PubMed - as supplied by publisher]
-
------

They better hurry up.

The LAIV is given by nasal spray and the patient becomes infected with it. The symptoms are mild and include a slight sore throat and a little fever that lasts about a day.

It looks to me like vaccination with a LAIV is a much better way to immunize people than by using killed virus plus an adjuvant. Over on Fluwiki, SusanC has raised hell about the use of adjuvants and her comments on this issue make interesting and disturbing reading. Here is the link:http://www.newfluwiki2.com/diary/35...n-a-pandemic-vi-squalene-antibodies-revisited

The LAIV does not require the use of an adjuvant and its use results in great protection within the nose and upper respiratory system, the usual place influenza tries to enter the body. Tests done in humans show those immunized with LAIV have slightly better outcomes that those vaccinated with killed virus for seasonal flu. New tests performed in animals just published show much better survival in animals given the a LAIV compared with killed virus using a pandemic strain (could be H5N1 or novel H1N1 but I can not recall). What was important though was the outcome when exposed to a more lethal virus than seasonal flu was much better using the LAIV than the injection with the same vaccine strain but killed before the jab.

GW